Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Attention-deficit hyperactivity disorder is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning.
The global attention-deficit/hyperactivity disorder (ADHD) therapeutics market is estimated to account for US$ 19,293.6 Mn in terms of value and is expected to reach US$ 29,996.9 Mn by the end of 2027.
Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Drivers
Increasing prevalence of attention-deficit/hyperactivity disorder is expected to propel growth of the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market over the forecast period. For instance, according to the study, ‘Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder among Adults and Children of Different Racial and Ethnic Groups.’ Published in the JAMA Network Open in November 2019, prevalence of attention-deficit/hyperactivity disorder in adults among 7 racial/ethnic groups increased from 0.43% in 2007 to 0.96% in 2016.
Moreover, R&D in attention-deficit/hyperactivity disorder is also expected to aid in growth of the market. For instance, in April 2020, American BriVision (Holding) Corporation announced that a site monitoring visit was conducted on March 10 and March 11, 2020 at the University of California San Francisco (UCSF) Medical Center for ABV-1505 Phase II Part I clinical trial, under the U.S. Food and Drug Administration (FDA) clinical protocol code BLI-1008-001, for Adult Attention-Deficit Hyperactivity Disorder (ADHD).
Stimulants held dominant position in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market in 2019, accounting for 86.1% share in terms of value, followed by non-stimulants, respectively.
Figure 1. Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market Share (%), by Value, by Drug Type, 2019
-therapeutics-market-fig-1.png "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics | Coherent Market Insights")
Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Restraints
Drug abuse (stimulants) is expected to hinder growth of the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market. Stimulants function by increasing dopamine levels in the brain, a neurotransmitter associated with pleasure, attention and movement. If stimulants are taken in doses and via routes other than prescribed, rapid and highly amplified increase in dopamine levels is achieved causing disruption in normal communication between brain cells resulting in euphoria, decreased appetite and wakefulness, which increases the risk of addiction.
Moreover, less availability of non-stimulant drugs is also expected to limit the demand for attention-deficit/hyperactivity disorder therapeutics. Although there is a risk of drug abuse associated with stimulants attention-deficit/hyperactivity disorder drugs, it currently accounts for a higher market share as compared to non-stimulants attention-deficit/hyperactivity disorder drugs. This is due to low availability of non-stimulants attention-deficit/hyperactivity disorder drugs in various geographies.
Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market Report Coverage
| Report Coverage |
Details |
| Base Year: |
2019 |
Market Size in 2019: |
US$ 18,133.1 Mn |
| Historical Data for: |
2016 to 2019 |
Forecast Period: |
2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: |
6.5% |
2027 Value Projection: |
US$ 29,996.9 Mn |
| Geographies covered: |
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
|
| Segments covered: |
- By Drug Type:
- Stimulants: Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate.
- Non-stimulants: Atomoxetine, Bupropion, Guanfacine, Clonidine.
- By Age Group: Pediatric and Adolescent, Adults.
- By Distribution Channel: Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, e-Commerce.
|
| Companies covered: |
Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.
|
| Growth Drivers: |
- Increasing prevalence of attention-deficit/hyperactivity disorder
- Increasing research and development
|
| Restraints & Challenges: |
- Side effects
- Drug abuse risks
|
Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Opportunities
Integration of attention-deficit/hyperactivity disorder knowledge improvement program into teachers’ educational programs is expected to offer lucrative growth opportunities for players in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market. For instance, in August 2020, researchers from Joint Program of Saudi Board in Community Medicine, Saudi Arabia, reported that only 16% and 22% of trial and control groups, respectively, showed adequate baseline knowledge about attention-deficit/hyperactivity disorder and that knowledge of teachers in the trial group significantly improved immediately after the intervention.
Moreover, adoption of antioxidants in attention-deficit/hyperactivity disorder treatment is also expected to aid in growth of the market. For instance, in February 2020, researchers from CONACYT-Hospital Infantil de México Federico Gómez, Mexico, reported that antioxidants could be considered as a multi-target adjuvant therapy for attention-deficit/hyperactivity disorder.
The global attention-deficit/hyperactivity disorder (ADHD) therapeutics market was valued at US$ 18,133.1 Mn in 2019 and is forecast to reach a value of US$ 29,996.9 Mn by 2027 at a CAGR of 6.5% between 2020 and 2027.
Figure 2. Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
-therapeutics-market-fig-2.png "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics | Coherent Market Insights")
Market Trends/Key Takeaways
Major players in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market are focused on R&D of new therapies to expand their product portfolio. For instance, in July 2020, American BriVision (Holding) Corporation reported the completion of the ABV-1505 Phase II Part I clinical trial for the treatment of adult attention-deficit/hyperactivity disorder.
Major players in the market are also focused on providing support programs during the COVID-19 pandemic. For instance, in April 2020, Otsuka Pharmaceutical Co., Ltd. extended its patient support programs, Otsuka Patient Support and Otsuka Patient Assistance Foundation, to provide “no-cost” access to its branded portfolio of prescription medicines for patients in the U.S. who have lost a job or health insurance coverage due to the COVID-19 pandemic.
Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Competitive Landscape
Major players operating in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market include, Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.
Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Key Developments
Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in March 2020, RespireRx Pharmaceuticals Inc. partnered with the UWM Research Foundation, Inc. to license GABA(A) receptor allosteric neuromodulator intellectual property from the UWM Research Foundation, Inc.
US :
INDIA :
UK :
JAPAN :
U.S. :
+1-206-701-6702
UK :
+44-020-8133-4027
JAPAN :
+81-50-5539-1737
INDIA :
+91-848-285-0837
Sales Office (U.S.) : 
